Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
GreenLight Biosciences Holdings, PBC Create: Alert

All | News | Filings
Date FiledTypeDescription
07/28/2023 8-K/A Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Third Amended and Restated Certificate of Incorporation of Greenlight Biosciences Holdings, PBC",
"Bylaws of Greenlight Biosciences Holdings, PBC",
"GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares",
"GreenLight Announces Completion of Merger with Fall Line Endurance Fund"
07/24/2023 8-K Quarterly results
07/13/2023 8-K/A Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
05/31/2023 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress"
03/28/2023 8-K Quarterly results
03/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
03/07/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
02/01/2023 8-K Quarterly results
01/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "GreenLight Biosciences and EpiVax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines ● The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design ● EpiVax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and differentiating highly immunogenic neo-antigens from epitopes that induce immune tolerance ● GreenLight will contribute proprietary RNA technology allowing mRNA design, formulation, and manufacturing"
11/09/2022 8-K Quarterly results
Docs: "GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ● Working toward clinical trial initiation for COVID vaccine candidate in 2023 ● Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India ● Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approval ● Honeybee solution EPA submission planned for 2023 ● Strategic realignment focused on near-term value drivers."
10/12/2022 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs...
09/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Deloitte & Touche LLP",
"Audited Consolidated Financial Statements of GreenLight Biosciences, Inc. as of and for the years ended December 31, 2021 and 2020",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations of GreenLight Biosciences, Inc. as of and for the years ended December 31, 2021 and 2020"
08/15/2022 8-K Quarterly results
08/01/2022 8-K Quarterly results
07/29/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
02/07/2022 8-K Asset disposition
Docs: "Certificate of Incorporation of GreenLight Biosciences Holdings, PBC",
"Second Amended and Restated Bylaws of GreenLight Biosciences Holdings, PBC",
"Letter from WithumSmith+Brown, PC to the U.S. Securities and Exchange Commission",
"List of Subsidiaries",
"Unaudited Pro Forma Condensed Combined Financial Information of Environmental Impact Acquisition Corp. and GreenLight Biosciences, Inc",
"Press Release"
02/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nasdaq: GRNA on February 3, 2022"
01/07/2022 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AUDITED BALANCE SHEET AS OF JANUARY 19, 2021"
01/05/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Letter Agreement",
"Form of Letter Agreement"
11/24/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
11/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Extended Subscription Agreements",
"Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp."
10/19/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
01/25/2021 8-K Quarterly results
01/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy